Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-finding study of KAF156 + lumefantrine solid dispersion for uncomplicated falciparum malaria
PACTR202104770362022Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, open-label trial of ganaplacide and lumefantrine in Malaria (12 cohorts), sponsored by Novartis. Primary endpoint: Effective dose determination. Started Dec 2016; status: completed.
02
Drugs
ganaplacidelumefantrine
03
Conditions
Malaria
Beyond the preview
Go deeper on PACTR202104770362022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202104770362022.